HRS-4642 + Adebrelimab + SHR-9839 + Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection + Cetuximab Solution for Infusion
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced KRAS G12D Mutant Solid Tumors
Conditions
Advanced KRAS G12D Mutant Solid Tumors
Trial Timeline
Jul 5, 2024 → Aug 1, 2026
NCT ID
NCT06385678About HRS-4642 + Adebrelimab + SHR-9839 + Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection + Cetuximab Solution for Infusion
HRS-4642 + Adebrelimab + SHR-9839 + Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection + Cetuximab Solution for Infusion is a phase 1/2 stage product being developed by Jiangsu Hengrui Medicine for Advanced KRAS G12D Mutant Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT06385678. Target conditions include Advanced KRAS G12D Mutant Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced KRAS G12D Mutant Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06385678 | Phase 1/2 | Active |
Competing Products
20 competing products in Advanced KRAS G12D Mutant Solid Tumors